Free breathing DCE-MRI with motion correction and its values for benign and malignant liver tumor differentiation  by Zheng, Xiaolin et al.
HOSTED BY Available online at www.sciencedirect.comScienceDirect
Radiology of Infectious Diseases 2 (2015) 65e71
www.elsevier.com/locate/jridResearch article
Free breathing DCE-MRI with motion correction and its values for benign
and malignant liver tumor differentiation
Xiaolin Zheng a, Lihua Xiao a,*, Xianmiao Fan a, Ning Huang b, Zihua Su b, Xiao Xu b
a Department of Radiology, Dongguan People's Hospital, Dongguan City, Guangdong Province, PR China
b GE Healthcare of China, Beijing City, PR China
Received 23 May 2015; revised 23 June 2015; accepted 20 July 2015
Available online 29 July 2015AbstractObjective: 3D dynamic contrast enhanced (DCE) MRI with parallel imaging, a novel method to understand tumor vascularization in vivo, has
been applied to liver in this work. Pharmacokinetics analysis could be performed with the help of motion correction by non-rigid registration
using the first pass data. The purpose of this study was to assess the feasibility of using this framework to differentiate benign and malignant
tumor in liver with DCE-MRI.
Material and methods: This prospective study was approved by the institutional review board, and informed consent was given by all patients. 48
Patients (56.1 ± 12.6 years old), with 51 pathologically confirmed liver tumor, were recruited in this study. All subjects underwent DCE-MRI
sequence with free-breathing, which was consisted of multi-flip angle contrast free image acquisition for T1 mapping, and a continuous
multiphase acquisition to capture contrast media wash in and out. Automatic non-linear image registration was applied to both multi-flip angle
data and dynamic phase data for motion correction. Parameters such as Ktrans, Vp, were then extracted by performing pharmacokinetic analysis
on the first pass data. Parameters from different types of tumor were evaluated by statistical analysis.
Results: All 48 patients successfully finished examinations and image quality was good for diagnosis purpose. Subjective comparisons between
original images and motion corrected images showed that images registration used in the paper can well control liver respiration motion and ROI
timeeintensity curve was much smoother after registration. 51 Visible lesions from 48 patients were analyzed. Pathological results revealed that
there were 15 benign (hepatic hemangioma) and 36 malignant (14 liver metastasis and 22 liver carcinomas) lesions. Statistical results showed
that benign and malignant tumors demonstrated significant differences ( p < 0.05) in their Ktrans values, with hepatic hemangioma (Ktrans
0.09 ± 0.04), liver metastasis (Ktrans 0.25 ± 0.08) and hepatic carcinoma (Ktrans 0.25 ± 0.10). Ktrans of malignant tumors was substantially higher
than benign ones. Vp values of the three types did not have statistical significance, with hepatic hemangioma (Vp 0.124 ± 0.176), liver metastasis
(Vp 0.164 ± 0.184) and hepatic carcinoma (Vp 0.162 ± 0.184).
Conclusion: Dynamic contrast-enhanced MRI combined with tracer kinetic model and non-rigid registration was a feasible method for diag-
nosing of liver lesions under free breezing mode. In our approach, the contrast agent transfer rate Ktrans was a good biomarker to differentiate
benign and malignant tumors of liver.
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is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Quantitative dynamic contrast-enhanced MRI (DCE-MRI)
allows us to produce pharmacokinetic parameters, that can
quantify endothelial permeability (Ktrans) and fractional blood
plasma volume (Vp) in tumors and tissues [1,2]. These pa-
rameters can provide additional information about micro-of Beijing You'an Hospital affiliated to Capital Medical University. This is an
licenses/by-nc-nd/4.0/).
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abdomen and have potentially important clinical values for
diagnosing disease and therapeutic planning. Previously, both
CT [3] and MR [4] were used to perform liver perfusion;
however, MR modality is noninvasive and noniodized and has
attracted more attentions recently. Dynamic contrast enhanced
MRI in liver has demonstrated good correlations between
perfusion as well as permeability parameters and the severity
of cirrhosis or fibrosis [5].
Previous research, in liver DCE-MRI, has several limita-
tions: firstly, liver suffers from motion artifacts brought by
respiration. This motion artifact could substantially affect
image quality and precision of the dynamic sequence [6]. A
rigid registration method was used to model and correct liver
motion in Ref. [7], but it cannot compensate for the actual
non-rigid motion in liver. Therefore, this can limit the preci-
sion of calculated parameters; secondly, perfusion time is too
long for the patient to cooperate. For example, in paper [7] the
author proposed to use a standard Tofts for data analysis. In
order to calculate Kep, a long scan sequence has to be per-
formed. However, results showed that only Ktrans has differ-
entiation capability. A simpler and robust Patlak [3] method
needs only first pass data to extract pharmacokinetic param-
eters. Thirdly, to eliminate motion artifacts, abdominal MRI
enhancement normally needs breath-hold [7], to get images
with better quality. But the data collected are non-continuous
and the continuous timeeintensity curves, especially inter-
mittent points in arterial input function, can be lost. Fourthly,
the majority of perfusion MR studies focus on a specific area
of tumor, failing to provide comprehensive evaluation of the
tumor as a whole.
To address the above problem in liver perfusion, we
adopted a continuous scanning procedure and motions were
aligned by a comprehensive non-rigid image registration al-
gorithm. Pharmacokinetic parameters were extracted by per-
forming Patlak analysis on the first pass perfusion data. The
purpose of this study was to assess the feasibility of using this
framework to differentiate benign and malignant tumor in liver
with DCE-MRI.
2. Materials and methods2.1. PatientsPatients inclusion criteria was: (1) age >18 years old. (2)
Patients were conscious and could finish the examination. (3)
Liver lesion was focal, with diameter >1.5 cm. (4) The lesion
was confirmed by histopathology. 61 Sequential patients be-
tween January, 2012 and August, 2013 were recruited in this
study, with 13 patients excluded (6 with lesions too small, and
7 with no histopathology results) and 48 patients included. The
48 patients (56.1 ± 12.6 years old) included 30 men (mean
age, 41 years; range, 25e80 years) and 18 women (mean age,
38 years; range, 24e71 years). There were a total of 51 visible
liver lesions found in the 48 patients. This study was approved
by the institutional review board and written informed consent
was obtained from all patients. Pathological results revealedthat there were 15 benign (hepatic hemangioma) and 36 ma-
lignant (14 liver metastasis and 22 liver carcinomas) lesions.2.2. DCE-MRI examination and data acquisitionsData was collected under free-breathing condition. All
patients rehearsed prior to examination to breathe slowly and
lightly. Patients were not scanned at any specific time of the
day and were not under any diet control.
The scanning was performed with a 3.0 T MRI (MAG-
NETOM Verio; Siemens Medical Systems, Erlangen, Ger-
many). The DCE-MRI protocol was composed of two parts, a
pre-contrast multi-flip angle sequence for T1 mapping and a
dynamic sequence to monitor contrast media flow in and out.
The flip and dynamic images were both acquired with a fast
T1 VIBE sequence using the same parameters but different flip
angles: TR/TE 4.4/0.9 ms; FOV 40 cm  40 cm; matrix
256  256; section thickness 5 mm; voxel size
2.6  1.6  5.0 mm; with 5.6 s temporal resolution. The T1
mapping sequence was composed of flip angles of 5, 10, 15,
20, 25 and 30, and the dynamic sequence with 50 consec-
utive sets of images were acquired with a flip angle of 10.
After the 2 sets dynamics images were acquired, 0.2 mmol per
kilo-gram of body weight of gadolinium-based contrast agent
(Gd-DTPA-BMA, Omniscan; GE) was injected intravenously
at 4 mL/s and followed by a 20-mL saline flush administered
at the same rate. Therefore, a total of 280 s of dynamic data
was collected.2.3. Motion correctionLiver, as a soft organ, suffers a lot from respiration motion
even after breathing training. Image registration has been used
for tackling motion correction in medical images for a while
[8]. Here we proposed a comprehensive nonlinear image
registration scheme to compensate liver motion. This regis-
tration scheme had to solve two problems in dynamic se-
quences, which are respiration motion and image brightness
difference brought by contrast injection. We used the free form
deformation algorithm in Ref. [6] as the main registration
engine and mutual information as correspondence metric [9]
to solve the brightness change problem. The algorithm was
implemented in Cþþ package NiftiReg [10], and the cost
function was optimized for liver motion in our implementa-
tion. Since we were working on 3D plus time domain data, our
proposed algorithm will work on 3D images (herein referred to
image). The whole registration scheme works as follows: 1) In
a dynamic sequence, an image n þ 1 is aligned with image n
using the above mentioned registration algorithm, denoting the
motion field between two images namely Mnþ1,n. 2) With this
motion field calculated, image n þ 1 could be deformed to
make it motion free from image n. 3) All motion fields be-
tween consecutive images were calculated. 4) To calculate
motion field between the first image and image n, we simply
sum up all motion fields from image 1 to image n by matrix
multiplication. Therefore, we can deform image n to make it
motion free from image 1.
67X. Zheng et al. / Radiology of Infectious Diseases 2 (2015) 65e712.4. MRI and pharmacokinetic modelingBefore any pharmacokinetic analysis can take place, MRI
intensityetime curve has to be converted to Gd based contrast
agent concentrationetime curve by using T1 mapping results
[8].
Patlak model was described by Jackson [11,12], it is a
reasonable simplification of the modified Tofts model,
CtðtÞ ¼ VpCpðtÞ þK transCpðtÞ5ekept
In Patlak analysis, assumption was made that the process of
contrast media across the vascular endothelial cell (Ktrans) was
mostly from capillary to extracellular extravascular space
(EES) and irreversibly (Kep) relatively small. Therefore, tissue
data from bolus arrival to first pass was used for extraction of
transfer constant, e.g. Ktrans map. Around 280 s data after in-
jection was used to fit the timeeintensity curve in our
implementation, which included different phases of the liver
enhancement.2.5. Data analysisMotion correction was assessed by means of visual com-
parison of shape of timeeintensity curve (TIC) on vessels and
tumors, before and after registration.
Two radiologists with more than five years of experience
browsed through dynamic sequence to find the lesion loca-
tions. Arterial input function (AIF) was placed on the proximal
abdominal aorta (at the level of coeliac axis). Region of in-
terest (ROI) was drawn along boundaries of the lesion with
necrosis, bleeding area, edema and vessels excluded, with the
ROI size normally ranged from 1 to 5 cm2. Then, this ROI was
placed on the result color maps to calculated mean value of
corresponding parameters. ROI was placed and parameters
were calculated on all 51 lesions. Pharmacokinetics parame-
ters of different types of tumor were compared with student t-
test and ANOVA (Matlab by Mathworks), a confidence level
of p < 0.05 was considered as statistical significant.
3. Results
Free-breathing DCE-MRI sequence was performed suc-
cessfully on all 48 patients. Subjective inspection showed that
non-rigid registration method can control body motion well.
After image registration, image distortion decreased between
consecutive image sets and portal vein braches became clearer
(Fig. 1). In Fig. 2, timeeintensity curves in portal vein before
and after registration were compared. It showed that after
registration, the timeeintensity curve had less noise and
became much smoother.
Pathological results revealed 51 lesions in 48 patients,
which included 15 benign (hepatic hemangioma) and 36 ma-
lignant (14 liver metastasis and 22 liver carcinoma). Their
corresponding pharmacokinetic values were shown in Table 1
and the value distribution was shown in Fig. 3. Color maps
were created that demonstrated the values of Ktrans and Vp foreach tumor type (HCC in Fig. 4, hemagioma in Fig. 5 and
metastasis in Fig. 6). ANOVA test results showed that there
was statistically significance of Ktrans among liver carcinoma,
liver metastasis and hepatic hemangioma (F ¼ 21.3,
p ¼ 2.46e-007 < 0.01). The student t-test was performed and
found that there was statistical significance between benign
and malignant tumor (t ¼ 6.586, p < 0.01), while there was no
statistical difference of Ktrans between liver carcinoma and
liver metastasis (t ¼ 0.0388, p ¼ 0.969). For Vp value, sta-
tistical results showed that there was no significant difference
between any two kinds among these three types of tumors
(F ¼ 0.24, p ¼ 0.788 > 0.05), ( p value between benign and
malignant tumor is 0.488, between hepatic carcinoma and liver
metastasis is 0.972). Tables 1 and 2 showed the complete
statistical results of different tumor types using ANOVA and
student t-test.
4. Discussions
Traditional liver tumor imaging focuses mostly on
morphology. However, with the introduction of targeted ther-
apy, treatment's pathological response often comes before
morphology change. With the development of 3 T MR, images
can be acquired with a higher SNR and higher temporal res-
olution [13] than 1.5 T MR. As a functional imaging method,
Dynamic Contrast Enhanced MR imaging enables character-
ization of microvascular structures and permeability in vivo
and is emerging as a promising method for monitoring tumor
response to treatment [1,14e16].
Compared with literature, we have contributed to the sci-
ence of liver DCE-MRI in several ways. Firstly, six flip angles
were measured in pre-contrast T1 mapping, which were more
than other literature [17]. More flip angles could provide more
accurate and robust T1 mapping than two flip angles method.
Secondly, all patients breathed freely during multiple phase
acquisitions of the whole liver, which achieved a temporal
resolution of 5.6 s per phase. It can be seen that non-rigid
registration can make the images motion free and this can
be helpful in performing accurate DCE-MRI analysis.
Compared with Yoshinori Hirashima et al. [18], who used
breath-hold, to eliminate respiration motion, our method can
provide a more accurate timeeintensity curve especially for
arterial input function (AIF). What's more, the amplitude of
breath holding could be different each time, and it could be
impossible for elder or sick patients to keep long breath
holding. Therefore, our free-breathing method with non-rigid
registration method can provide more accurate DCE-MRI re-
sults and are applicable to a broader group of patients.
Thirdly, Compared with literature [7], we collected a larger
group of patients with more types of tumor. We proposed
using a pharmacokinetic model, which can produce pharma-
cokinetic parameter by only processing the first pass of the
contrast media. Compared with the Tofts model as in Ref.
[19], this model can potentially lower the acquisition time by
sacrificing one parameter. However, as it can be seen from our
scanning protocol, our scan time is longer enough to support
Tofts model and this can leave us some future direction to
Fig. 1. Mosaic images with black blocks showed one phase and white phase showed the following phase. Left image was one before registration, where liver cyst
deforming and fragmented portal vein branches were seen (red arrow). Right image was one after registration where cyst deforming was unobvious and portal vein
branches were clear (green arrow).
Fig. 2. Images shows timeeintensity curve (TIC) before (top) and after
(bottom) registration with an ROI placed on portal vein. It showed that after
registration, TIC becomes much smoother.
Fig. 3. Left: the distributions of all Ktrans values of benign and malignant liver
cancer; right: the mean and standard deviation of hepatic carcinoma (left),
hepatic hemangioma (middle) and liver metastasis (right).
68 X. Zheng et al. / Radiology of Infectious Diseases 2 (2015) 65e71compare the model difference between Patlak and Tofts
methods. If more evidences support that shorter scanning time
is enough to differentiate benign and malignant liver tumors,
as needed in Patlak Model, we will be shortening our MR
scanning time later on.
This method was successfully applied to all patients. It can
be seen from results, that there was statistically significant
difference between Ktrans from benign and malignant tumors
( p < 0.01, student t-test), while there was no statistical sig-
nificant difference between Ktrans of liver carcinoma and liver
metastasis ( p ¼ 0.9693). For Vp value, statistical resultsTable 1







Cases (n) 22 14 15
Ktrans 0.25 ± 0.097 0.249 ± 0.076 0.09
Vp 0.162 ± 0.184 0.164 ± 0.184 0.12
Their mean ± std, as well as F values, p values were shown. We could reject the nul
could not reject the null hypothesis that Vp of different lesions were equal.showed that there was no significant difference between any
two kinds among these three types of tumors ( p value between
benign and malignant tumor is 0.4384, between hepatic car-
cinoma and liver metastasis is 0.6951). In Flaherty KT et al.
[20], 32 patients with colorectal liver metastases were treated
with cytotoxicity drug. They found the Ktrans as well as Vp
values decreased with the anti-angiogenesis treatments, the
differences are statistically significant. It illustrates that the
parameters are correlated well with the tumor activity. And it
demonstrates that micro-circulation and endothelial perme-
ability have important biological effect on the tumor. How-
ever, these experiments were performed with free-breathe
method, without any image correction applied. Our proposed
free-breath with image non-rigid registration can help in
extracting more realistic parameters.
In validation, we proved that the produced Ktrans can be
used as a biomarker and classifier for benign and malignant
liver tumor differentiations. What's more, the proposed phar-
macokinetic model showed potential to produce parametersatic
angioma
F Value p Value 0.01
2 ± 0.0404 21.3 2.46e-007 <0.01
4 ± 0.176 0.24 0.788 [0.05
l hypothesis that Ktrans of different lesions were equal with p ¼ 2.46e-7, but we
Fig. 4. (a) A DCE-MRI image showed hepatic carcinoma on the right lobe (arrow); (b) Ktrans map showed higher permeability values of the lesion (arrow)
compared with surrounding parenchyma, indicating increased vascularity; (c) Vp map was also shown (arrow).
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save valuable time. Although, Vp did not show any differen-
tiation capability between any types of tumor, it is likely to
subjective to the model we choose. We will further validate
DCE-MRI technique with a broader choice of models and
different protocols. Although this study showed values in
differentiation between benign and malignant liver lesions,
other benign lesions such as focal nodular hyperplasia,
adenocarcinoma, and malignant lesions such asFig. 5. (a) A DCE-MRI image showed hepatic hemangioma on the right lobe (arr
(arrow), but no necrosis area was presented; (c) Vp map was also shown (arrow).cholangiocarcinoma were not included into the study, because
of the limited cases available. These cases will be analyzed
when the number is large enough for statistical analysis.
5. Conclusions
We proposed a liver DCE-MRI technique with free
breathing and motion correction. The tracer kinetic modeling
can produce stable uninterrupted data, clear images duringow); (b) Ktrans map showed slightly higher permeability values on the lesion
Fig. 6. (a) A DCE-MRI image showed hepatic metastasis on the right lobe (arrow); (b) Ktrans map showed increased permeability values around the lesion (arrow),
indicating increased vascularity; (c) Vp map was also shown (arrow).
Table 2
Student t test between Ktrans of benign and malignant lesions, and between









t Value 6.5863 5.9312 6.9974 0.0388
p Value of Ktrans 2.90e-008 9.51e-007 1.60e-007 0.969
It showed that statistically significant difference existed between benign and
malignant lesions, but not between hepatic carcinoma and liver metastasis, the
two types of malignant lesions.
70 X. Zheng et al. / Radiology of Infectious Diseases 2 (2015) 65e71passage of the contrast agent under free-breathing mode.
Hence Ktrans is a potential biomarker in differentiation of he-
patic benign and malignant tumors.
Source of funding
Funding for the study was provided by the Guangdong
Province Science Funds: social development projects
(2011B031800372).
References
[1] Materne R, Smith AM, Peeters F, Dehoux JP, Keyeux A, Horsmans Y,
et al. Assessment of hepatic perfusion parameters with dynamic MRI.
Magn Reson Med 2002;47(1):135e42.
[2] Patel J, Sigmund EE, Rusinek H, Oei M, Babb JS, Taouli B. Diagnosis of
cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic
contrast-enhanced MRI alone and in combination: preliminary experience.
J Magn Reson Imaging 2010;31(3):589e600.
[3] Hayano K, Desai GS, Kambadakone AR, Fuentes JM, Tanabe KK,
Sahani DV. Quantitative characterization of hepatocellular carcinoma andmetastatic liver tumor by CT perfusion. Cancer Imaging
2013;13(4):512e9.
[4] Vriens Dennis, Hanneke WM, van Laarhoven, Krabbe PF, Visser EP,
Heerschap A, et al. Chemotherapy response monitoring of colorectal liver
metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters
and 18F-FDG PET metabolic rate. J Nucl Med 2009;50:1777e84.
[5] Hagiwara M, Rusinek H, Lee VS, Losada M, Bannan MA, Krinsky GA,
et al. Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR
imagingdinitial experience. Radiology 2008;246(3):926e34.
[6] Rueckert D, Sonoda LI, Hayes C, Hill DLG, Leach MO, Hawkes DJ.
Nonrigid registration using free-form deformations application to breast
MR images. IEEE Trans Med Imaging 1999;18(8):712e21.
[7] Rao SX, Chen CZ, Liu H, Zeng MS, Qu XD. Three-dimensional whole-
liver perfusion magnetic resonance imaging in patients with hepatocellu-
lar carcinomas and colorectal hepatic metastases. BMC Gastroenterol
2013;25:13e53.
[8] Lange T, Wenckebach TH. Registration of different phases of contrast-
enhanced CT/MRI data for computer-assisted liver surgery planning:
evaluation of state-of-the-art methods. Int J Med Robot 2005;1(3):6e20.
[9] Josien PWP, Antoine Maintz JB, Viergever MA. Mutual information based
registration of medical images: a survey. IEEE Trans Med Imaging
2003;22(8):986e1004.
[10] Modat Marc, McClelland Jamie, Ourselin Sebastien. Lung registration
using the NiftyReg package. EMPIRE10, Grand Chall MICCAI. 2010.
[11] Li KL, Zhu XP, Waterton J, Jackson A. Improved 3D quantitative
mapping of blood volume and endothelial permeability in brain tumors. J
Magn Reson Imaging 2000;12(2):347e57.
[12] Ewing JR, Knight RA, Nagaraja TN, Yee JS, Nagesh V, Whitton PA, et al.
Patlak plots of Gd-DTPA MRI data yield bloodebrain transfer constants
concordant with those of 14C-sucrose in areas of bloodebrain opening.Magn
Reson Med 2003;50(2):283e9.
[13] Fu¨tterer JJ, Scheenen TW, Huisman HJ, Klomp DW, van Dorsten FA,
Hulsbergen-van de Kaa CA, et al. Initial experience of 3 Tesla endorectal
coil agnetic resonance imaging and 1H-spectroscopic imaging of the
prostate. Invest Radiol 2004;39(11):671e80.
[14] Li KL, Zhu XP, Checkley DR, Tessier JJ, Hillier VF, Waterton JC, et al.
Simultaneous mapping of blood volume and endothelial permeability
71X. Zheng et al. / Radiology of Infectious Diseases 2 (2015) 65e71surface area product in gliomas using iterative analysis of first-pass dy-
namic contrast enhanced MRI data. Br J Radiol 2003;76:39e50.
[15] Hacklander T, Hofer M, Reichenbach, Rascher K, Furst G, Modder U.
Cerebral blood volume maps with dynamic contrast-enhanced T1-
weighted FLASH imaging: normal values and preliminary clinical re-
sults. J Comput Assist Tomogr 1996;20:532e9.
[16] Scharf J, Zapletal C, Hess T, Hoffmann U, Mehrabi A, Mihm D, et al.
Assessment of hepatic perfusion in pigs by pharmacokinetic analysis of
dynamic MR images. J Magn Reson Imaging 1999;9(4):568e72.
[17] Zanette Brandon, Cron Greg O, Nguyen Thanh B, Dehoux JP, Keyeux A.
Accuracy of quantitative 3D DCE-MRI using variable flip angle T1
mapping, B1 correction, and the bookend method. Proc Intl Soc Mag
Reson Med 2013;21:220e30.[18] Hirashima Yoshinori, Yamada Yasuhide, Tateishi Ukihide, Kato K,
Miyake M, Horita Y, et al. Pharmacokinetic parameters from 3-Tesla
DCE-MRI assurrogate biomarkers of antitumor effects of bev-
acizumabplus FOLFIRI in colorectal cancer with liver metastasis. Int J
Cancer 2012;130:2359e65.
[19] Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV,
et al. Estimating kinetic parameters from dynamic contrast-enhanced
T(1)-weighted MRI of a diffusable tracer: standardized quantities and
symbols. J Magn Reson Imaging 1999;10:223e32.
[20] Flaherty KT, Rosen MA, Heitjan DF, Gallagher ML, Schwartz B,
Schnall MD, et al. Pilot study of DCE-MRI to predict progression-free
survival with sorafenib therapy in renal cell carcinoma. Cancer Biol
Ther 2008;7:496e501.
